Market Overview:
The global uterine cancer diagnostic testing market is expected to grow at a CAGR of 6.5% from 2018 to 2030. The market growth is attributed to the increasing incidence of uterine cancer, technological advancements in the field of diagnostics, and rising demand for early diagnosis and treatment. Ultrasound scanning is the most commonly used diagnostic technique for uterine cancer. It helps in detecting tumors as well as their size and location. Biopsy procedures are also used for diagnosis, which involves taking a small sample of tissue from the tumor for examination under a microscope. Blood tests are also used to detect biomarkers associated with uterine cancer. These tests help in determining the stage of disease and guiding treatment decisions. The global uterine cancer diagnostic testing market is segmented by type into ultrasound scanning, biopsy procedures, and blood tests. By application, it is segmented into hospitals, ambulatory surgical centers (ASCs), cancer research institutes (CRIs), specialized clinics, diagnostic laboratories (DLs), and others (including academic institutions). Geographically, it is segmented into North America,, Latin America,, Europe,, Asia Pacific,,and Middle East & Africa,. The North American region dominates the global market due to high prevalence of uterine cancers coupled with increasing adoption ratesof advanceddiagnostic technologies. However,.
Product Definition:
Uterine cancer diagnostic testing is a process used to detect the presence of uterine cancer. This type of testing can include various types of scans, biopsies, and blood tests. The importance of this type of testing is that it can help to determine the best course of treatment for a person who has been diagnosed with uterine cancer.
Ultrasound Scanning:
Ultrasound scanning is a diagnostic procedure that uses high-frequency sound waves to create images of internal body organs and tissues. The procedure is painless, safe, and noninvasive. Ultrasound scanning devices are available in the market in various forms such as transducers, probes & accessories, software & hardware etc.
Biopsy Procedures:
A biopsy is a surgical procedure used to obtain tissue or fluid for examination. Biopsy procedures are most commonly used in the diagnosis of cancer, but they can also be used for other conditions such as intestinal diseases and infections, skin lesions, and bone disorders. A biopsy may be done to confirm a suspected disorder or to look for evidence of an existing disease condition.
Application Insights:
Based on application, the global market is segmented into hospitals, ambulatory surgical centers, specialized clinics/cancer hospitals and diagnostic laboratories. Hospitals held the largest share in 2017 owing to availability of advanced healthcare facilities and a large number of U.S. FDA-approved diagnostic imaging devices and equipment for accurate diagnosis at single location.
The use of transvaginal ultrasound has increased significantly over past few years owing to its non-invasive nature that helps in visualizing the entire uterus without making any cuts on body surface; this factor is anticipated to fuel growth during forecast period as it allows precise measurement of tumor size which was not possible before due to limitations imposed by conventional methods such as biopsy or surgery procedures used for obtaining tissue samples from body surfaces such as abdomen or breast glandulars (glands that produce milk).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, availability of advanced technologies and high adoption rate for technologically advanced procedures. Moreover, increasing cases of cancer are also contributing towards regional growth. For instance, as per statistics published by American Cancer Society in 2018, around 1 million new cases were estimated to be diagnosed in U.S during the year 2016 which is higher than previous years. Such alarming trends have compelled major companies operating within this industry to come together and form coalitions that will help them share information regarding research grants offered by organizations like National Cancer Institute (NCI) or other funds provided by government agencies for cancer research studies etc.
Growth Factors:
- Increasing incidence of uterine cancer
- Rising awareness about uterine cancer and its diagnostic tests
- Growing demand for minimally invasive diagnostic procedures for uterine cancer
- Technological advancements in the field of diagnostics for uterine cancer 5. increasing healthcare expenditure
Scope Of The Report
Report Attributes
Report Details
Report Title
Uterine Cancer Diagnostic Testing Market Research Report
By Type
Ultrasound Scanning, Biopsy Procedures, Blood Tests
By Application
Hospitals, Ambulatory Surgical Centers, Cancer Research Institutes, Specialized Clinics, Diagnostic Laboratories, Others
By Companies
Abbott, Roche Holdings, Siemens, Danaher, BioMerieux
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
187
Number of Tables & Figures
131
Customization Available
Yes, the report can be customized as per your need.
Global Uterine Cancer Diagnostic Testing Market Report Segments:
The global Uterine Cancer Diagnostic Testing market is segmented on the basis of:
Types
Ultrasound Scanning, Biopsy Procedures, Blood Tests
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Ambulatory Surgical Centers, Cancer Research Institutes, Specialized Clinics, Diagnostic Laboratories, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott
- Roche Holdings
- Siemens
- Danaher
- BioMerieux
Highlights of The Uterine Cancer Diagnostic Testing Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Ultrasound Scanning
- Biopsy Procedures
- Blood Tests
- By Application:
- Hospitals
- Ambulatory Surgical Centers
- Cancer Research Institutes
- Specialized Clinics
- Diagnostic Laboratories
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Uterine Cancer Diagnostic Testing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Uterine cancer diagnostic testing may include a physical examination, blood tests, and imaging studies.
Some of the major players in the uterine cancer diagnostic testing market are Abbott, Roche Holdings, Siemens, Danaher, BioMerieux.
The uterine cancer diagnostic testing market is expected to grow at a compound annual growth rate of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Uterine Cancer Diagnostic Testing Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Uterine Cancer Diagnostic Testing Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Uterine Cancer Diagnostic Testing Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Uterine Cancer Diagnostic Testing Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Uterine Cancer Diagnostic Testing Market Size & Forecast, 2018-2028
4.5.1 Uterine Cancer Diagnostic Testing Market Size and Y-o-Y Growth
4.5.2 Uterine Cancer Diagnostic Testing Market Absolute $ Opportunity
Chapter 5 Global Uterine Cancer Diagnostic Testing Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Uterine Cancer Diagnostic Testing Market Size Forecast by Type
5.2.1 Ultrasound Scanning
5.2.2 Biopsy Procedures
5.2.3 Blood Tests
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Uterine Cancer Diagnostic Testing Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Uterine Cancer Diagnostic Testing Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Ambulatory Surgical Centers
6.2.3 Cancer Research Institutes
6.2.4 Specialized Clinics
6.2.5 Diagnostic Laboratories
6.2.6 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Uterine Cancer Diagnostic Testing Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Uterine Cancer Diagnostic Testing Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Uterine Cancer Diagnostic Testing Analysis and Forecast
9.1 Introduction
9.2 North America Uterine Cancer Diagnostic Testing Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Uterine Cancer Diagnostic Testing Market Size Forecast by Type
9.6.1 Ultrasound Scanning
9.6.2 Biopsy Procedures
9.6.3 Blood Tests
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Uterine Cancer Diagnostic Testing Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Ambulatory Surgical Centers
9.10.3 Cancer Research Institutes
9.10.4 Specialized Clinics
9.10.5 Diagnostic Laboratories
9.10.6 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Uterine Cancer Diagnostic Testing Analysis and Forecast
10.1 Introduction
10.2 Europe Uterine Cancer Diagnostic Testing Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Uterine Cancer Diagnostic Testing Market Size Forecast by Type
10.6.1 Ultrasound Scanning
10.6.2 Biopsy Procedures
10.6.3 Blood Tests
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Uterine Cancer Diagnostic Testing Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Ambulatory Surgical Centers
10.10.3 Cancer Research Institutes
10.10.4 Specialized Clinics
10.10.5 Diagnostic Laboratories
10.10.6 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Uterine Cancer Diagnostic Testing Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Uterine Cancer Diagnostic Testing Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Uterine Cancer Diagnostic Testing Market Size Forecast by Type
11.6.1 Ultrasound Scanning
11.6.2 Biopsy Procedures
11.6.3 Blood Tests
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Uterine Cancer Diagnostic Testing Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Ambulatory Surgical Centers
11.10.3 Cancer Research Institutes
11.10.4 Specialized Clinics
11.10.5 Diagnostic Laboratories
11.10.6 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Uterine Cancer Diagnostic Testing Analysis and Forecast
12.1 Introduction
12.2 Latin America Uterine Cancer Diagnostic Testing Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Uterine Cancer Diagnostic Testing Market Size Forecast by Type
12.6.1 Ultrasound Scanning
12.6.2 Biopsy Procedures
12.6.3 Blood Tests
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Uterine Cancer Diagnostic Testing Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Ambulatory Surgical Centers
12.10.3 Cancer Research Institutes
12.10.4 Specialized Clinics
12.10.5 Diagnostic Laboratories
12.10.6 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Uterine Cancer Diagnostic Testing Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Uterine Cancer Diagnostic Testing Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Uterine Cancer Diagnostic Testing Market Size Forecast by Type
13.6.1 Ultrasound Scanning
13.6.2 Biopsy Procedures
13.6.3 Blood Tests
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Uterine Cancer Diagnostic Testing Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Ambulatory Surgical Centers
13.10.3 Cancer Research Institutes
13.10.4 Specialized Clinics
13.10.5 Diagnostic Laboratories
13.10.6 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Uterine Cancer Diagnostic Testing Market: Competitive Dashboard
14.2 Global Uterine Cancer Diagnostic Testing Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbott
14.3.2 Roche Holdings
14.3.3 Siemens
14.3.4 Danaher
14.3.5 BioMerieux
